The adult epilepsy market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan)…
Read More
Affinia Therapeutics Secures FDA Orphan Drug Designation for AFTX-201, a Promising Gene Therapy for BAG3-Associated Dilated Cardiomyopathy
Affinia Therapeutics has announced a significant milestone in the development of its investigational gene therapy, AFTX-201, with the US Food…
Read More
Fungal gene editing world-first points to promising cancer medicines
A groundbreaking development from the University of Pennsylvania (PA, USA) has introduced a sophisticated gene-editing platform, fPE7max, specifically optimized for…
Read More
Ipsen Acquires Rare Disease Specialist Memo Therapeutics for up to €700 Million, Bolstering Pipeline with Promising BK Polyomavirus Asset
Paris, France – In a significant strategic move to expand its rare disease portfolio, global biopharmaceutical company Ipsen announced today…
Read More
Sanofi’s Nexviazyme Demonstrates Promising Results in Infants with Infantile-Onset Pompe Disease, Paving Way for Potential Label Expansion
Sanofi’s groundbreaking treatment for Pompe disease, Nexviazyme (avalglucosidase alfa), has achieved a significant milestone with the successful completion of the…
Read More
DNA Aptamers Offer a Promising New Frontier in Identifying and Targeting Senescent Cells for Aging and Disease Research
One of the most significant hurdles in unraveling the complexities of aging and a spectrum of diseases lies in the…
Read More
Takara Bio Unveils Groundbreaking Instrument-Free Spatial Transcriptomics Workflow, Promising Unprecedented Accessibility and Resolution
SAN FRANCISCO, CA – Takara Bio, a leading developer of life science research tools, has announced the introduction of a…
Read More
SpliSense Advances Promising Cystic Fibrosis Therapy with Significant Funding and Phase IIb Trial Launch
The biotech firm SpliSense is making significant strides in the development of a novel therapy for cystic fibrosis, announcing a…
Read More
AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026
AvenCell Therapeutics presented updated results for its CAR-T cell blood cancer therapy at EHA 2026. The European Hematology Association (EHA)…
Read More
ASCO 2026: Navigating the Evolving Landscape of Non-Small Cell Lung Cancer with Promising Data from Eli Lilly and Mixed Reactions for Summit/Akeso
The American Society of Clinical Oncology (ASCO) 2026, held from May 29 to June 2, 2026, served as a critical…
Read MoreYOU MAY HAVE MISSED
